Skip to main navigation

Stoke Therapeutics

Join Our Team
Contact Us

About Us
Our Story
Our Science
Our Work in Dravet
Our Pipeline
Investors & Media

Media Room

Media Room

For media inquiries, please contact:

Dawn Kalmar
Chief Communications Officer
781-303-8302
dkalmar@stoketherapeutics.com

Fact Sheets

TANGO Explainer

Dravet Syndrome Fact Sheet

Autosomal Dominant Optic Atrophy Fact Sheet

Photos

Leadership

Edward M. Kaye, M.D., CEO & Director 236.1 KB

Graphics

Illustrations

TANGO-ASO illustration 4 MB

Logos

Stoke Therapeutics (JPG) 112.5 KB

Key Publications

Source

Science Translational Medicine

|

August 26, 2020

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Source

Nature Communications

|

July 9, 2020

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Genetic Epilepsies Presentations

Source

AES 2020

|

December 4, 2020

Observational Study to Investigate Cognition and Other Non-seizure Comorbidities in Children and Adolescents with Dravet Syndrome: Baseline Analysis of the BUTTERFLY Study

Source

AES 2020

|

December 4, 2020

Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A Reduces Seizures and Rescues Parvalbumin Positive Interneuron Firing Frequency in a Mouse Model of Dravet Syndrome

Source

AES 2020

|

December 4, 2020

Reducing the Time to Diagnosis and Increasing the Detection of Individuals with SCN1A-Related Disease Through a No-cost, Sponsored Epilepsy Genetic Testing Program

Source

AES 2020

|

December 4, 2020

Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A Reduces Seizures and Rescues Parvalbumin Positive Interneuron Firing Frequency in a Mouse Model of Dravet Syndrome – Oral Presentation

Source

AES 2020

|

December 4, 2020

Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study

Source

AES 2019

|

December 8, 2019

TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate

Source

AES 2019

|

December 7, 2019

Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a Prevents SUDEP in a mouse model of Dravet Syndrome

Neuro-Ophthalmology Presentations

May 4, 2021

Antisense oligonucleotide mediated increase in OPA1 improves mitochondrial function in fibroblasts derived from patients with autosomal dominant optic atrophy (ADOA)

Source

ARVO 2020

|

June 12, 2020

Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy

Source

ASGCT 2020

|

May 12, 2020

POSTER: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy

Press Releases

May 18, 2021

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

May 10, 2021

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 4, 2021

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

Toolkit

Email Alerts

Contact IR

FAQ

© 2021 Stoke Therapeutics,
all rights reserved.

Terms of Use
Privacy Policy

Home
About Us
- Leadership
- Board of Directors
- Scientific Advisory Board
- COVID-19 Statement
- Racial Equity
Our Story
Our Science
Our Work in Dravet
Our Pipeline
Investors & Media
- Overview
- Media Room
- Press Releases
- Events & Presentations
- Financials & SEC Filings
- Stock Information
- Analyst Coverage
- Governance
Join Our Team
Contact Us